APUS Key Statistics, Chart & Performance
The current stock price of APUS is 2.9 USD. In the past month the price increased by 42.16%.
APUS Latest News, Press Relases and Analysis
APUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About APUS
Company Profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Company Info
APIMEDS PHARMACEUTICALS US I
100 Matawan Road, Suite 325
Matawan NEW JERSEY US
Employees: 2
Phone: 18482015010
APIMEDS PHARMACEUTICALS US I / APUS FAQ
What does APIMEDS PHARMACEUTICALS US I do?
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
What is the current price of APUS stock?
The current stock price of APUS is 2.9 USD. The price increased by 32.42% in the last trading session.
Does APUS stock pay dividends?
APUS does not pay a dividend.
What is the ChartMill rating of APIMEDS PHARMACEUTICALS US I stock?
APUS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy APUS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APUS.
What is APIMEDS PHARMACEUTICALS US I worth?
APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 36.48M USD. This makes APUS a Nano Cap stock.
APUS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to APUS.
APUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APUS. APUS has a great financial health rating, but its profitability evaluates not so good.
APUS Financial Highlights
Over the last trailing twelve months APUS reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -78.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.18% | ||
| ROE | -14.27% | ||
| Debt/Equity | 0 |